CA-ARRCUS
18.7.2024 15:01:36 CEST | Business Wire | Press release
Arrcus, the hyperscale networking software company and a leader in core, edge, and multi-cloud routing and switching infrastructure, today announced a significant new investment of $30 million from Prosperity7 Ventures, NVIDIA, Lightspeed, Hitachi Ventures, Liberty Global, Clear Ventures, and General Catalyst. Growing investor interest in the company comes alongside Arrcus’ success with leading Fortune 500 and Global 2000 customers and will enable the company to expand platform support, accelerate growth, and continue delivering cost-effective and transformational networking solutions to customers worldwide.
As the unprecedented adoption of AI continues, there is a growing need for distributed networking to improve the efficiency of compute infrastructure spanning datacenter, 5G, edge and hybrid/multi-cloud environments across enterprise, cloud, and network operators. Arrcus’ uniquely differentiated routing and switching platform, Arrcus Connected Edge (ACE), features a distributed microservices architecture that is flexible, high-performance, scalable, fully programmable, modular, and hybrid cloud-ready. It is deployable on various form factors, including data processing units (DPUs), merchant silicon, and compute, and enables a wide range of use cases including low-latency data center networking, modern edge deployments, telco access and transport, and hybrid multi-cloud connectivity.
Arrcus’ ACE networking platform, leveraging the NVIDIA BlueField DPU, enables customers to efficiently offload, accelerate, and isolate compute-intensive networking applications like security and traffic engineering. With the advent of GenAI applications, this gives customers the ability to have high performance secure connectivity within the data center, while delivering higher utilization and power efficiency for compute-intensive workloads.
"We are thrilled to welcome NVIDIA as our latest investor and look forward to building on our collaboration. Arrcus’ leading networking software coupled with NVIDIA's AI infrastructure will help deliver maximum efficiency to customers from data centers as well as their edge and cloud computing environments," said Shekar Ayyar, Chairman and CEO of Arrcus. "We also extend our gratitude to Prosperity7, Lightspeed, Hitachi Ventures, Liberty Global, Clear Ventures, and General Catalyst for their continued support and confidence in our vision."
This collaboration between NVIDIA and Arrcus can help extend AI data center architectures to distributed configurations supported by modular designs such as the NVIDIA MGX platform.
“Modern networks are evolving to address customer needs in the era of AI,” said Kevin Deierling, senior vice president of networking at NVIDIA. “We’re collaborating with Arrcus to provide high-performance, secure and cost-efficient data center networking for a variety of accelerated computing applications.”
Arrcus is garnering significant attention for its innovative networking software solutions that enable businesses to achieve substantial cost savings while improving scalability, performance, and reliability in core, edge, and multi-cloud infrastructures. Arrcus networking is ideally suited for the telecom, financial services, and industrial verticals, amongst others.
“AI is driving the need for more flexible networking to maximize the impact of high-performance compute cycles,” said Jason Hardy, CTO for AI, Hitachi Vantara. “We are pleased to see Arrcus software working across leading industry hardware platforms for distributed datacenter networking.”
“We are excited to see the new investment in Arrcus. Arrcus networking has the potential for high performance at lower cost for datacenter and carrier networks, as well as meeting the demands of infrastructure for AI and 5G,” said Adrian Drury, MD Platform Technology Liberty Global.
“Arrcus is driving an exciting disruption in networking for datacenters and AI. After leading their D round, we are now excited to join NVIDIA and other investors in continuing to support their growth and platform adoption among leading customers,” said Abhishek Shukla, Managing Director, Prosperity7 Ventures.
"Arrcus continues to push the boundaries of networking innovation with their ACE platform. Their unique approach to leveraging distributed microservices architecture and integration with leading hardware platforms enables a wide range of networking use cases from the edge to datacenters to multi-clouds, setting them apart in the industry,” said Alan Weckel, Co-Founder and Technology Analyst at 650 Group. “This new investment further validates Arrcus' vision and capability to deliver high-performance, scalable, and cost-efficient networking solutions that meet the evolving demands of AI-driven environments."
For more information please click here.
Additional Resources
- Arrcus to demonstrate secure 5G networking on NVIDIA BlueField-3 DPUs
- Arrcus Delivers Next Generation of High-Performance, Zero-Trust Networking for Datacenters Enabled by NVIDIA BlueField
- Investor interest in Arrcus grows as Hitachi Ventures is latest to join Series D
About Arrcus
Arrcus is a leading provider of networking software solutions that empower businesses to achieve unparalleled scalability, performance, and reliability in their infrastructure. Arrcus is disrupting the industry with disaggregated solutions that deliver innovative, agile, and cost-effective networking, allowing enterprises to break free from traditional, monolithic systems and embrace a more flexible, efficient, and scalable approach to modern networking. The Arrcus team consists of world-class technologists who have an unparalleled record in shipping industry-leading networking products, complemented by industry thought leaders, operating executives, strategic partners, and top-tier VCs. The company is headquartered in San Jose, Calif. For more information, go to www.arrcus.com or follow Arrcus on LinkedIn and Twitter/X.
About Prosperity7
Prosperity7 Ventures (P7) is the diversified growth fund of Aramco Ventures, a subsidiary of Aramco, the world's leading integrated energy and chemicals company. The fund's name derives from "Prosperity Well', the 7th oil well drilled in Saudi Arabia and the first to strike oil. Taking forward this pioneering history, P7 invests globally with a long-term view in breakthrough technologies and transformational business models that will bring prosperity and positive impact on a vast scale.
For more information, please visit https://www.prosperity7vc.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718299242/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom